Valuation: Cartesian Therapeutics, Inc.

Market Cap 19Cr 17Cr 16Cr 14Cr 27Cr 1.74TCr 27Cr 187.21Cr 74Cr 934.49Cr 70Cr 68Cr 2.96TCr P/E 2026 *
-2.84x
P/E 2027 * -1.71x
Enterprise Value 4.45Cr 4.04Cr 3.73Cr 3.37Cr 6.36Cr 417.45Cr 6.59Cr 45Cr 18Cr 224.02Cr 17Cr 16Cr 709.59Cr EV / Sales 2026 *
106x
EV / Sales 2027 * -365x
Free-Float
48.29%
Yield 2026 *
-
Yield 2027 * -
1 day-4.25%
1 week-13.39%
Current month-6.32%
1 month-3.03%
3 months-31.22%
6 months-17.62%
Current year-15.67%
1 week 6.06
Extreme 6.06
7.09
1 month 6.01
Extreme 6.01
7.9
Current year 5.6
Extreme 5.6
11
1 year 5.6
Extreme 5.6
11
3 years 5.6
Extreme 5.6
42.6
5 years 5.6
Extreme 5.6
42.6
10 years 5.6
Extreme 5.6
42.6
Date Insider Type Main position Quantity % Market Cap. Importance
02/04/26 Exercice 7,58,001 2.8594%
02/04/26 Exercice 22,740 --
02/04/26 Exercice 22,740 --
Change 5-day change 1-year change 3-year change Capi.($)
-4.25%-13.39%-18.50%-80.70% 19Cr
-1.29%-3.91%+51.98%+69.06% 6.63TCr
-0.09%+2.79%+12.54%+95.02% 6.06TCr
+0.63%+1.64%+23.11%+89.70% 5.55TCr
-1.26%-1.45%+12.43%+117.42% 4.76TCr
-0.15%-5.06%+20.00%+29.27% 4.37TCr
-3.15%-16.63%+146.30%+685.27% 3.73TCr
+0.23%+2.14%+14.85%+46.22% 3.66TCr
+2.35%-3.61%+80.65%+60.70% 3.22TCr
+1.42%+5.84%-36.40%+402.78% 2.66TCr
Average -0.56%-2.41%+30.70%+151.47% 4TCr
Weighted average by Cap. -0.29%-1.13%+35.86%+152.65%

Financials

2026 *2027 *
Net sales 4L 4L 4L 3L 6L 3.94Cr 6L 42.31L 16.76L 2.11Cr 15.73L 15.4L 6.69Cr 3L 3L 2L 2L 4L 2.68Cr 4L 28.84L 11.43L 1.44Cr 10.72L 10.49L 4.56Cr
Net income -6.39Cr -5.81Cr -5.37Cr -4.85Cr -9.15Cr -600.23Cr -9.47Cr -65Cr -26Cr -322.1Cr -24Cr -23Cr -1.02TCr -12Cr -11Cr -10Cr -9.37Cr -18Cr -1.16TCr -18Cr -124.79Cr -49Cr -622.91Cr -46Cr -45Cr -1.97TCr
Net Debt -14Cr -13Cr -12Cr -11Cr -20Cr -1.32TCr -21Cr -142.33Cr -56Cr -710.48Cr -53Cr -52Cr -2.25TCr -29Cr -26Cr -24Cr -22Cr -41Cr -2.72TCr -43Cr -292.44Cr -115.87Cr -1.46TCr -108.71Cr -106.41Cr -4.62TCr
Projected Income Statement - Annual - Cartesian Therapeutics, Inc.
Logo Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc. is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.
Employees
75
Date Price Change Volume
16/26/16 $6.080 -4.25% 97,902
13/26/13 $6.350 -0.08% 1,06,818
12/26/12 $6.355 -7.63% 2,64,906
11/26/11 $6.880 -0.15% 1,34,092
10/26/10 $6.890 -1.85% 94,864
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cartesian Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
6.080USD
Average target price
33.67USD
Spread / Average Target
+453.73%
  1. Stock Market
  2. Stocks
  3. RNAC Stock